D'OXYVA® (deoxyhemoglobin vasodilator) is the latest and most advanced non-invasive transdermal (over the skin) infusion technology on the market intended for a variety of health, athletic, and cosmetic benefits and is empowering each and every one of us to quickly take control of even severe conditions in about 4-8 weeks. You can measure results by yourself at home with consumer and medical diagnostics, consult your physician and interpret your results.
After years of studies and user feedback, D'OXYVA has shown significant improvements in:
• cardiovascular activity (in over 80%**) of users leading to much improved physical activity and mobility, which, as part of a healthy diet and lifestyle, may help significantly
• reduce the risk of chronic wounds (by over 75%*),
• reduce the risk of high blood pressure (by over 45%*),
• reduce the risk of hypertension, cholesterol (by over 45%*), and
• reduce the risk of diabetes (by over 55%*).
All this in 2 to 3 months with an average use of 5 minutes a day and 5 times a week because D'OXYVA may start delivering outcomes in as short as 2 weeks. (*Average effect depending on dose, severity of condition, comorbidities and other factors. **Average result is based on number of enrolled subjects in each clinical study with D'OXYVA and user feedback.) READ IMPORTANT PATIENT INFORMATION.
Based on our in-depth global market research, we are confident that D'OXYVA is a simpler, faster, and more affordable health solution than other therapies on the market today.
Get your D'OXYVA today with a box of cartridge supplies and experience the benefits after just a 5-minute daily D'OXYVA solution sprayed gently on your thumb or healthy skin on any problematic area on your body.
No electricity or harmful chemicals are required, just about an ounce of clean drinking water filled in D'OXYVA's Water Capsule to operate the device.
Jesse Golden recommends D'OXYVA in Viva Glam Magazine
"This is a revolutionary hand held device that delivers CO2 into the body in a molecular form. It increases oxygen levels to areas that need it. I was recommended by someone to be somewhat of a Guinea pig for my chronic illness (rheumatoid arthritis). I was amazed at how the swelling and stiffness in my joints went away and I had more energy. The best part is they market this product also for its beauty benefits. It can help with acne, wrinkles, spider veins, stretch marks and cellulite! Check out Circularity!"(read expert and user reviews)
D'OXYVA FOR PRESCRIPTION BY HEALTH EXPERTS
D'OXYVA® (deoxyhemoglobin vasodilator) is becoming a standard setter in numerous fields and the first choice of doctors around the world for the treatment of the most difficult complications caused by chronic diseases such as diabetes, cardiovascular, and various forms of cancer such as multiple myeloma.
D'OXYVA is intended for significant enhancements in the regulation of the autonomic nervous system (ANS) including tissue microcirculation with cellular oxygenation (Bohr & Haldane effect), which is being recognized in a rapidly growing number of published randomized clinical trials leading to a variety of significant clinical outcomes. In short, D'OXYVA has demonstrated unmatched increases in blood circulation, cellular oxygenation, tissue perfusion in the microvessels, and neural signal activation in the autonomic nervous system according to randomized human clinical trials.
Microcirculation dysfunction is increasingly regarded by the mainstream scientific medical community as the underlying cause of the most widespread health complications for both the young and elderly. Among other things, restrictions in these processes impede the flow of antibodies, white blood cells and platelets, and rob the skin and body of oxygen.
D'OXYVA is a relatively affordable low risk, non-invasive, non-toxic, both adjunct and standalone solution for the forward-looking health facility and patient wanting to significantly reduce cost of treatment and readmission rates, while improving patient compliance. The recommended average starting dose of D'OXYVA is 16g CO2 twice daily for 5 days per week for the first 2 weeks and once daily for 5 days per week for another 2 weeks. The average maintenance dose of D'OXYVA can be once a day for 3 days per week. The starting and maintenance dose of D'OXYVA should be individualized according to patient characteristics such as goals of therapy and response. Blood flow (perfusion index), oxygen (SpO2 and TcPO2), blood pressure, blood glucose, heart rate variability (sympathetic/parasympathetic nerve activity), blood pH, and other vital levels should be analyzed within 2 to 4 weeks after starting D'OXYVA and dosage adjusted according to results. Stopping D'OXYVA after only 4 weeks is not recommended and it may not provide the expected long-term benefits even if major benefits and clinical outcomes were realized!
D'OXYVA is becoming exceptionally advantageous for the patient, health care practitioner, and the entire healthcare system, and is starting to provide substantial cost savings and improvements in quality of life for a wide variety of health complications for people of all ages and backgrounds.
"There are a lot of possibilities here and we are really excited about conducting future studies to determine what D'OXYVA may be able to provide to people with microvascular disease."
THE MOST STUDIED & AFFORDABLE, FASTEST, LOWEST RISK,
MEDICAL GAS-POWERED, HANDHELD,
NON-INVASIVE TRANSDERMAL DEVICE (NTD)
D'OXYVA has been demonstrating numerous significant health benefits for years in record time with zero adverse side effect reports and hundreds of thousands of successful applications. D'OXYVA has been reviewed, studied, and used at leading institutions around the world such as Penn State University, Florida State University, Valley Presbyterian Hospital, Hospital Kuala Lumpur, Airlangga University, Chulalongkorn University, University of Szeged, National Taipei University and others. Learn more about the various benefits of D'OXYVA.
and vital signs in just 4-8 weeks with zero adverse events
This is why we established Circularity Healthcare in early 2011 after years of research and development and now, we are an emerging multinational leader in proprietary circulatory and non-invasive applications. Learn more about Circularity Healthcare.
D'OXYVA® (deoxyhemoglobin vasodilator) is being recognized and touted by medical thought-leaders in the United States and many other countries as an upcoming industry-leading painless health technology that promises to change the dynamics of how health care is delivered at health care facilities and at home.
D'OXYVA is a CE-marked medical device (Class I, low risk). Circularity is seeking approvals via the U.S. FDA and in other countries for delivery of Medical Gases such as Medical Carbon Dioxide (USP UN1013) via a novel patented non-invasive transdermal route with D'OXYVA as treatment for various widespread conditions.
Medical Carbon Dioxide is manufactured and delivered under applicable standards per each country's regulatory requirements. In the United States, the Food and Drug Administration has cleared the use of Medical Carbon Dioxide for the route of inhalation for humans but not yet for transdermal delivery with D'OXYVA. Transportation of Medical Carbon Dioxide via any postal or courier service requires certification for handling Dangerous Goods (HAZMAT) by the U.S. Department of Transportation (DOT). Use of unapproved substances and products may be illegal, cause serious injury, and even death!
WARNING! Ask your physician before using D'OXYVA FOR MEDICAL AND CLINICAL RESEARCH PURPOSES, prescription only. The D'OXYVA transdermal delivery device holds a growing number of Class I (low risk) medical device licenses around the world. Use for non-medical purposes is available over-the-counter (OTC) and in various retail stores online and offline. Circularity's novel D'OXYVA patented transdermal drug delivery pathway with FDA-cleared Medical Carbon Dioxide (UN1013) has not been evaluated yet by the U.S. Food and Drug Administration (FDA) and is not intended to diagnose, treat, cure, or prevent any disease. The information provided on this Website is for educational and research purposes and is not intended to replace medical advice. Learn more